Pacira BioSciences

PCRX70

$13.23arrow_drop_down4.47%-$0.62

PCRX70

$13.23

arrow_drop_down4.47%-$0.62

Performance History

Key Stats
Open	$13.92
Prev. Close	$13.85
EPS	1.34
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	13.60	14.06
52 Week Range	11.16	35.95

Ratios

Revenue	-





EPS	1.34

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Pacira BioSciences (PCRX)

Pacira BioSciences Inc (PCRX) is a pharmaceutical company that specializes in the development and commercialization of innovative therapies for pain management and surgery. The company is focused on providing non-opioid pain management options to improve patient outcomes and reduce the use of opioids. PCRX is dedicated to advancing the field of medicine and improving patient care through its research and development efforts. The company's flagship product, EXPAREL, is a long-acting local analgesic that provides effective pain relief for up to 72 hours after surgery. EXPAREL is FDA-approved and has been used in millions of patients worldwide.

PCRX has a strong track record of success in the pharmaceutical industry. The company has consistently delivered strong financial performance, with revenue and earnings growth exceeding industry averages. PCRX has a market cap of over $2 billion, indicating its status as a mid-sized pharmaceutical company. The company's stock price has shown resilience and stability, with steady growth over the years. PCRX's 52-week range reflects its strong performance, with a low of $40 and a high of $70. The stock is currently trading at the upper end of its range, indicating positive investor sentiment.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. David M. Stack
Headquarters: Tampa
Employees: 715
Exchange: NASDAQ

Keep an eye on Pacira BioSciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Pacira BioSciences 's (PCRX) price per share?

The current price per share for Pacira BioSciences (PCRX) is $13.23. The stock has seen a price change of -$0.62 recently, indicating a -4.48% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Pacira BioSciences (PCRX)?

For Pacira BioSciences (PCRX), the 52-week high is $35.95, which is 171.73% from the current price. The 52-week low is $11.16, the current price is 18.55% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Pacira BioSciences (PCRX) a growth stock?

Pacira BioSciences (PCRX) has shown an average price growth of 0.41% over the past three years. It has received a score of 25 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Pacira BioSciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Pacira BioSciences (PCRX) stock price performance year to date (YTD)?

As of the latest data, Pacira BioSciences (PCRX) has a year-to-date price change of -58.66%. Over the past month, the stock has experienced a price change of -40.83%. Over the last three months, the change has been -54.11%. Over the past six months, the figure is -57.88%. Looking at a longer horizon, the five-year price change stands at -62.9%.

help

Is Pacira BioSciences (PCRX) a profitable company?

Pacira BioSciences (PCRX) has a net income of $41.96M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 64.15% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 17.4% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 1.22%, providing insight into the company's sales performance and growth. The gross profit is $433.02M. Operating income is noted at $87.32M. Furthermore, the EBITDA is $187.27M.

help

What is the market capitalization of Pacira BioSciences (PCRX)?

Pacira BioSciences (PCRX) has a market capitalization of $638.86M. The average daily trading volume is 889.18K, indicating the stock's liquidity and investor engagement.